FiercePharma12h
FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout
A new FDA approval stands to give Daiichi Sankyo’s Turalio some company in a rare tumor type. | The new FDA approval gives ...
Local students delve into biotech engineering with new APW-BioSpherix collaboration
A new partnership between APW High School and local innovator BioSpherix is focusing on real world knowledge and exposure.
BioPharma Dive1d
A brain biotech launches with Roche’s spare parts
Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch.
Longwood Fund launches anxiety drug developer with $93.5M investment
A Boston VC firm is launching a new neuroscience company with a $93M investment that aims to treat disorders including ...
PulseSight Therapeutics Announces First Close of its Series A Financing to Fund Clinical Development of PST-611 in dry AMD
PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces the first close of its ...
FierceBiotech2d
VC Longwood Fund unveils neuro biotech with $93M, assets licensed from Roche
Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...
News Medical5d
Ariceum Therapeutics receives FDA’s Orphan Drug Designation for targeted radionuclide cancer treatment
Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food ...